基层心衰中心优化管理心力衰竭患者1例

Abstract
Figure/Table
References (19)
Related Citation (15)

Download: PDF (570 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Chronic heart failure (CHF) is a serious manifestation and late stage of various heart diseases with high mortality and re-hospitalization rate. Since 2017, China Cardiovascular Health Alliance has initiated the construction and certification project of China Heart Failure Center, leading hospitals at all levels in China to carry out standardized diagnosis, treatment and management of this disease. Since the establishment of the primary heart failure Center in 2019, the Department of Cardiology of Shanghai Ruijin Rehabilitation Hospital has received whole-course guidance from the Heart failure Demonstration Center, professional medical training and optimized management of patients inside and outside the hospital. The two sides work together to achieve precise treatment and manage heart failure patients in the region. This report presents a case of a 57-year-old male patient who is corpulent and has reduced ejection fraction. After two years of clinic follow-up and medication optimum at the primary heart failure center. The structural abnormalities of his heart were ameliorated, the left ventricular ejection fraction has increased. Blood sugar, weight, and abdominal circumference tend to be normal, the risk of hospitalization and death is reduced, and improves his life quality and ability to function.

Key words： Heart failure center Medication Out of hospital monitoring Optimize management

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2022/V29/I13/164

[1]	Ong MK，Romano PS，Edgington S，et al.Effectiveness of Remote Patient Monitoring After Discharge of Hospitalized Patients With Heart Failure：The Better Effectiveness After Transition-Heart Failure （BEAT-HF）Randomized Clinical Trial[J].JAMA Internal Med，2016，176（3）：310-318.
[2]	Preiss D，Campbell RT，Murray HM，et al.The effect of statin therapy on heart failure events：a collaborative meta-analysis of unpublished data from major randomized trials[J].Eur Heart J，2015，36（24）：1536-1546.
[3]	Faris RF，Flather M，Purcell H，et al.Diuretics for heart failure[J].Cochrane Database Syst Rev，2012，（2）：CD003838.
[4]	Guo WQ，Li L.Angiotensin converting enzyme inhibitors for heart failure with reduced ejection fraction or left ventricular dysfunction：a complementary network meta-analyses[J].Int J Cardiol，2016，214：10-12.
[14]	Kaplinsky E.DAPA-HF trial：dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure[J].Drugs Context，2020，9：2019-11-3.
[15]	American Diabetes Association.Standards of Medical Care in Diabetes—2021[J].Diabetes Care，2021，44（suppl 1）：s34-s232.
[19]	中国医师协会心血管内科医师分会心力衰竭学组，中国心衰中心联盟专家委员会.中国心力衰竭诊断与治疗质量评价和控制指标专家共识[J].中国医学前沿杂志（电子版），2021，13（3）：52-62.
[5]	Packer M，Coat AJ，Fowler MB，et al.Effect of carvedilol on suivival in severe chronic heart failure[J].N Engl J Med，2001，344（22）：1651-1658.
[6]	McMurray JJ，Packer M，Desai AS，et al.Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure[J].N Engl J Med，2014，371（11）：993-1004 .
[7]	Swedberg K，Komajda M，Bhm M，et al.Ivabradine and outcomes in chronic heart failure （SHIFT）：a randomised placebo-controlled studyl[J].Lancet，2010，376（9744）：875-885.
[8]	中华医学会心血管病学分会心力衰竭学组，中国医师协会心力衰竭专业委员会，中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志. 2018 （10）：760-789.
[9]	Akshay S，Scott D，Amil M，et al.Effect of Sacubitril-Val sartan vs. Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction A Randomized Clinical Trial[J].JAMA，2019，322（11）：1077-1084.
[10]	James L，Margaret F，Javed B，et al.Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction[J].JAMA，2019，322（11）：1085-1095.
[11]	Zugck C，Strk S，Stckl G.Long-term treatment with ivabradine over 12 months in patients with chronic heart failure in clinical practice：Effect on symptoms， quality of life and hospitalizations[J].Int J Cardiol，2017，240：258-264.
[12]	Marso SP，Daniels GH，Brown-Frandsen K，et al.Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes[J].N Engl J Med，2016，375（4）：311-22.
[13]	Wiviott SD，Raz I，Bonaca MP，et al.Dapagliflozin and cardiovascular outcomes in type 2 diabetes[J].N Engl J Med，2019，380（4）：347-357.
[16]	Feng P，Yu DM，Chen LM，et al.Liraglutide reduces the body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients[J].Acta Pharmacol Sin，2015，36（2）：200-208.
[17]	Horie I，Abiru N，Hongo R，et al.Increased sugar intake as a form of compensatory hyperphagia in patients with type 2 diabetes under dapagliflozin treatment[J].Diabetes Res Clin Pract，2018，135：178-184.
[18]	Bolinder J，Ljunggren O，Kullberg J，et al.Effects of dapagliflozin on body weight，total fat mass，and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin[J].J Clin Endocrinol Metab，2012，97（3）：1020-1031.